Compare RAMP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | RCKT |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 534.2M |
| IPO Year | 1994 | N/A |
| Metric | RAMP | RCKT |
|---|---|---|
| Price | $27.72 | $4.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $35.60 | $29.65 |
| AVG Volume (30 Days) | 875.5K | ★ 2.9M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $745,580,000.00 | N/A |
| Revenue This Year | $11.15 | N/A |
| Revenue Next Year | $9.10 | $97.68 |
| P/E Ratio | $24.52 | ★ N/A |
| Revenue Growth | ★ 13.02 | N/A |
| 52 Week Low | $21.71 | $2.19 |
| 52 Week High | $35.20 | $8.80 |
| Indicator | RAMP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 58.97 |
| Support Level | $27.91 | $2.99 |
| Resistance Level | $29.05 | $5.34 |
| Average True Range (ATR) | 1.13 | 0.38 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.21 | 51.16 |
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.